Ophir

Ophir Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation adeno-associated virus (AAV) gene therapies for rare monogenic diseases. Founded by leading experts in viral vector design from the University of Massachusetts Chan Medical School, the company leverages a proprietary platform to engineer AAV capsids with enhanced tissue specificity and reduced immunogenicity. Their primary pipeline targets lysosomal storage disorders, including Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis, with the goal of providing definitive treatments for these devastating conditions. By optimizing vector delivery and expression, Ophir aims to overcome the limitations of current gene therapy approaches in treating central nervous system and systemic disorders.